LLY

824.17

+0.68%↑

JNJ

155.87

-0.66%↓

ABBV

191.35

+0.4%↑

NVO

78.32

-1.78%↓

UNH

308.73

-1.44%↓

LLY

824.17

+0.68%↑

JNJ

155.87

-0.66%↓

ABBV

191.35

+0.4%↑

NVO

78.32

-1.78%↓

UNH

308.73

-1.44%↓

LLY

824.17

+0.68%↑

JNJ

155.87

-0.66%↓

ABBV

191.35

+0.4%↑

NVO

78.32

-1.78%↓

UNH

308.73

-1.44%↓

LLY

824.17

+0.68%↑

JNJ

155.87

-0.66%↓

ABBV

191.35

+0.4%↑

NVO

78.32

-1.78%↓

UNH

308.73

-1.44%↓

LLY

824.17

+0.68%↑

JNJ

155.87

-0.66%↓

ABBV

191.35

+0.4%↑

NVO

78.32

-1.78%↓

UNH

308.73

-1.44%↓

Search

Biogen Inc

Open

SectorGezondheidszorg

129.97 -0.35

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

128.11

Max

130.42

Belangrijke statistieken

By Trading Economics

Inkomsten

-26M

241M

Verkoop

-24M

2.4B

K/W

Sectorgemiddelde

13.269

51.748

EPS

3.02

Winstmarge

9.893

Werknemers

7,605

EBITDA

19M

554M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+25.56% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-762M

20B

Vorige openingsprijs

130.32

Vorige sluitingsprijs

129.97

Nieuwssentiment

By Acuity

50%

50%

142 / 381 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Biogen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 sep 2024, 11:00 UTC

Top Nieuws

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Biogen Inc Prognose

Koersdoel

By TipRanks

25.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 164.05 USD  25.56%

Hoogste 255 USD

Laagste 115 USD

Gebaseerd op 29 Wall Street-analisten die 12-maands prijsdoelen bieden voor Biogen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

29 ratings

13

Buy

16

Hold

0

Sell

Technische score

By Trading Central

118.15 / 121.17Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

142 / 381 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.